KALV

8.30

0.61% 0.05

Dopo l'orario di chiusura: 8.30

Kalvista Pharmaceuticals Inc (KALV)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$8.25

Aprire:

$8.35

Volume 24 ore:

269.68K

Relative Volume:

0.79

Capitalizzazione di mercato:

$410.17M

Reddito:

Utile/perdita netta:

$-108.30M

Rapporto P/E:

-2.6349

EPS:

-3.15

Flusso di cassa netto:

$-97.15M

1 W Prestazione:

+5.73%

1M Prestazione:

-4.05%

6M Prestazione:

-44.56%

1 anno Prestazione:

-36.15%

Intervallo 1D:

$8.19

$8.42

Intervallo di 1 settimana:

$7.30

$8.42

Portata 52W:

$7.30

$16.88

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Nome

Kalvista Pharmaceuticals Inc

Settore

Healthcare (1174)

Industria

Biotechnology (684)

Telefono

(857) 999-0075

Indirizzo

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Dipendente

150

Cinguettio

@kalvista

Prossima data di guadagno

2024-09-05

Ultimi documenti SEC

KALV's Discussions on Twitter

Confronta KALV con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KALV Kalvista Pharmaceuticals Inc	8.30	410.17M	0	-108.30M	-97.15M	-3.15
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-07	Iniziato	TD Cowen	Buy
2024-12-18	Iniziato	BofA Securities	Buy
2020-06-15	Iniziato	H.C. Wainwright	Buy
2019-07-29	Iniziato	SVB Leerink	Outperform
2019-03-20	Iniziato	Needham	Buy
2018-10-30	Iniziato	Jefferies	Buy
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2017-08-31	Iniziato	BTIG Research	Buy

Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

Jan 19, 2025

KalVista wins new Buy at BofA on potential of lead candidate - MSN

Jan 19, 2025

Jan 16, 2025

Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 16, 2025

Jan 08, 2025

KalVista Pharmaceuticals Awards Strategic Employee Stock Options Worth 111,000 Shares - StockTitan

Jan 08, 2025

TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN

Jan 08, 2025

TD Cowen backs Kalvista stock as peak sales potential for sebetralstat exceeds $750MM - Investing.com Canada

Jan 08, 2025

Jan 07, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD Cowen - MarketBeat

Jan 07, 2025

Jan 02, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Holdings Raised by Geode Capital Management LLC - Defense World

Jan 02, 2025

Jan 01, 2025

Barclays PLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 01, 2025

Dec 26, 2024

How the (KALV) price action is used to our Advantage - Stock Traders Daily

Dec 26, 2024

Dec 25, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by State Street Corp - MarketBeat

Dec 25, 2024

State Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 25, 2024

Dec 23, 2024

KalVista Pharmaceuticals Inc (NASDAQ: KALV) Is The Number One Stock Currently Moving. - Stocks Register

Dec 23, 2024

Dec 20, 2024

KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada

Dec 20, 2024

Dec 18, 2024

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha

Dec 18, 2024

BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia

Dec 18, 2024

KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha

Dec 18, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat

Dec 18, 2024

Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 18, 2024

Dec 17, 2024

KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada

Dec 17, 2024

Dec 16, 2024

KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com

Dec 16, 2024

KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian

Dec 16, 2024

KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan

Dec 16, 2024

Dec 13, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 10, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Dec 10, 2024

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com

Dec 09, 2024

What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat

Dec 09, 2024

What is HC Wainwright’s Forecast for KALV FY2029 Earnings? - Defense World

Dec 09, 2024

Dec 08, 2024

KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Dec 08, 2024

Dec 07, 2024

KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Dec 07, 2024

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook - Investing.com

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria

Dec 06, 2024

Dec 05, 2024

KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks

Dec 05, 2024

180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat

Dec 05, 2024